Germany Archives

News and Trends 9 Sep 2015

FDA will use a European Bioinformatics tool to keep patients safe

Molecular Health, a bioinformatics company based in Heidelberg, Germany, today announced that it will enter a commercial-licensing agreement with the US Food and Drugs Standard Agency (FDA) to implement their new bioanalytical product SafetyMAP to analyse risk of marketed drugs. Molecular Health (Labiotech Map Profile here), partnered with MD Anderson (TX) early on, doing consultancy […]

September 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 7 Sep 2015

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

MD Anderson is expanding its Immatics sharehold to spawn new Houston-based subsidiary Immatics US through investing into a $60M (€54M) pot. Also partnering up with French CAR-T pioneers Cellectis, and collaborating with German Merck, MD Anderson is seemingly wanting to immerse itself in the European immuno-oncology field. As a shareholder in the German cancer immunotherapy […]

September 7, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Sep 2015

Startups receive €25K investment as part of Merck’s brand new Accelerator Program

Merck – the German healthcare company has announced the 3 start-ups it plans to adopt into its in-house accelerator program. Two of the participants focus on e-health, while the third, Sulfotools, has developed a cleaner and cheaper method of solid-phase protein synthesis (SPPS). Merck has awarded these start-ups with a €25K investment as a ‘silent’ investor as […]

September 3, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 1 Sep 2015

Does your business plan need some enhancement? The Science4Life Venture Cup 2016 kicks off today!

The application for Germany’s Science4Life Venture Cup 2016 is now open! Join the competition to meet sector-specific experts, benefit from the experiences of former participants and win up to €25k to help your startup to get to the next level. Labiotech knows from its own experience that an aspiring startup needs a convincing business plan […]

September 1, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 1 Sep 2015

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

A new research competition is born. The European Society of Cardiology and Boehringer Ingelheim will award €400k to four research projects treating cardiovascular diseases. Big Pharmas like to give a push to aspiring research projects within their field. GSK is a key partner of the world’s largest life science startup accelerator, namely OneStart. Sanofi is engaged […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 25 Aug 2015

Leading German Biotechs MorphoSys and Immatics partner to pump up their Immuno-Oncology Therapies

Two German biotechs with highly successful platforms join forces to fight cancer. MorphoSys and Immatics Biotechnologies want to generate novel antibody-based therapeutics against multiple cancer antigens. They are two of the thriving forces in the German biotech scene. Munich’s MorphoSys claims having developed the most successful antibody library technology in the pharma industry, currently has 100 […]

August 25, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Aug 2015

Roche abandons Wilex to Make Way for Immuno-Oncology

Roche just dropped a first-generation antibody-based treatment preventing cancer cells from proliferating. Interestingly enough, the partner of the collaboration, Wilex’ subsidiary Heidelberg Pharma, stated the research “progressed well, on schedule, and in a mutually satisfactory manner”. What happened? Heidelberg Pharma is a German company that discovers new drugs using its platform technology for antibody drug […]

August 13, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 13 Aug 2015

Emmanuelle Charpentier, co-discoverer of CRISPR-Cas9 Technology, comes to Berlin!

French, young and brilliant, Emmanuelle Charpentier will now be working as a director at the Max Planck Institute for Infection Biology in Berlin! Emmanuelle Charpentier is labeled one of the most influential scientists by the Time magazine when she discovered THE new technology of the century: CRISPR-Cas9. Among numerous honors, she won the $3M Breakthrough Prizes […]

August 13, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 10 Aug 2015

Evotec enters Immuno-Oncology and Diabetes Therapy with Help from Sanofi

Evotec had to announce a setback recently when its Alzheimer’s treatment in collaboration with Roche failed in Phase IIb. However, another strong partner on its side, Sanofi, never lost trust in the German biotech’s value. In the last three days, the French giant entered into two new projects with Evotec, which target diabetes and immuno-oncology. […]

August 10, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Aug 2015

Bill & Melinda Gates’ Faith in CureVac is Leading to a New Program

CureVac, a pioneer in the field of mRNA-based technology, today announced that the company has initiated its third target product development program in collaboration with the Bill & Melinda Gates Foundation. The program will leverage CureVac’s RNActive technology platform in the development of a prophylactic vaccine to protect against respiratory syncytial virus (RSV), adding to […]

August 7, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 31 Jul 2015

MorphoSys Tackles the Technical Challenge of GPCR-targeted Drugs

Germany-based MorphoSys AG announced today that its partner Heptares Therapeutics, has initiated a therapeutic antibody program arising from the alliance the companies entered into in February 2013. Heptares will use MorphoSys’s antibody library to generate a new candidate targeting a GPCR, one of the largest class of pharmaceutical target currently on the market. In February 2013, MorphoSys and Heptares […]

July 31, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 30 Jul 2015

Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

Boehringer Ingelheim puts a new pillar in its oncology pipeline. The German giant acquired a Phase II compound for the treatment of lung cancer from the Korean pharma company Hamni. Non-small cell lung cancer makes up about 90% of all lung cancers. A targeted therapy includes the inhibition of the epidermal growth factor receptor (EGFR), […]

July 30, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us